The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
Conclusion: The results of this analysis can serve as a foundation to introduce HRQoL-based recommendations for the use of biologics in the management of IBD in Saudi Arabia.
PMID: 32619388 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Crohn's Disease | Economics | Health Management | Humira | Inflammatory Bowel Disease | Middle East Health | Pain | Pain Management | Remicade | Saudi Arabia Health | Study | Ulcerative Colitis